311 related articles for article (PubMed ID: 27528699)
1. Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
Rogers LM; Mott SL; Smith BJ; Link BK; Sahin D; Weiner GJ
Clin Cancer Res; 2017 Feb; 23(4):954-961. PubMed ID: 27528699
[No Abstract] [Full Text] [Related]
2. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
3. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD).
Fritsche LG; Lauer N; Hartmann A; Stippa S; Keilhauer CN; Oppermann M; Pandey MK; Köhl J; Zipfel PF; Weber BH; Skerka C
Hum Mol Genet; 2010 Dec; 19(23):4694-704. PubMed ID: 20843825
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
5. Contribution of copy number variation in the regulation of complement activation locus to development of age-related macular degeneration.
Schmid-Kubista KE; Tosakulwong N; Wu Y; Ryu E; Hecker LA; Baratz KH; Brown WL; Edwards AO
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5070-9. PubMed ID: 19553609
[TBL] [Abstract][Full Text] [Related]
6. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
[TBL] [Abstract][Full Text] [Related]
8. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.
Zhu L; Zhai YL; Wang FM; Hou P; Lv JC; Xu DM; Shi SF; Liu LJ; Yu F; Zhao MH; Novak J; Gharavi AG; Zhang H
J Am Soc Nephrol; 2015 May; 26(5):1195-204. PubMed ID: 25205734
[TBL] [Abstract][Full Text] [Related]
9. Copy number variation in the complement factor H-related genes and age-related macular degeneration.
Kubista KE; Tosakulwong N; Wu Y; Ryu E; Roeder JL; Hecker LA; Baratz KH; Brown WL; Edwards AO
Mol Vis; 2011; 17():2080-92. PubMed ID: 21850184
[TBL] [Abstract][Full Text] [Related]
10. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.
Zipfel PF; Edey M; Heinen S; Józsi M; Richter H; Misselwitz J; Hoppe B; Routledge D; Strain L; Hughes AE; Goodship JA; Licht C; Goodship TH; Skerka C
PLoS Genet; 2007 Mar; 3(3):e41. PubMed ID: 17367211
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
12. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
13. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
15. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.
Charbonneau B; Maurer MJ; Fredericksen ZS; Zent CS; Link BK; Novak AJ; Ansell SM; Weiner GJ; Wang AH; Witzig TE; Dogan A; Slager SL; Habermann TM; Cerhan JR
Am J Hematol; 2012 Sep; 87(9):880-5. PubMed ID: 22718493
[TBL] [Abstract][Full Text] [Related]
16. Genetic influences on plasma CFH and CFHR1 concentrations and their role in susceptibility to age-related macular degeneration.
Ansari M; McKeigue PM; Skerka C; Hayward C; Rudan I; Vitart V; Polasek O; Armbrecht AM; Yates JR; Vatavuk Z; Bencic G; Kolcic I; Oostra BA; Van Duijn CM; Campbell S; Stanton CM; Huffman J; Shu X; Khan JC; Shahid H; Harding SP; Bishop PN; Deary IJ; Moore AT; Dhillon B; Rudan P; Zipfel PF; Sim RB; Hastie ND; Campbell H; Wright AF
Hum Mol Genet; 2013 Dec; 22(23):4857-69. PubMed ID: 23873044
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
18. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
[TBL] [Abstract][Full Text] [Related]
19. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
[TBL] [Abstract][Full Text] [Related]
20. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
